CTCL
MCID: PRM373
MIFTS: 52

Primary Cutaneous T-Cell Non-Hodgkin Lymphoma (CTCL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

MalaCards integrated aliases for Primary Cutaneous T-Cell Non-Hodgkin Lymphoma:

Name: Primary Cutaneous T-Cell Non-Hodgkin Lymphoma 11
Cutaneous T-Cell Lymphoma 11 19 75 14 16
Lymphoma, T-Cell, Cutaneous 43 71
Cutaneous T Cell Lymphoma 11 14
Lymphoma T-Cell Cutaneous 53
Ctcl 19

Classifications:



External Ids:

Disease Ontology 11 DOID:0060061
MeSH 43 D016410
NCIt 49 C3467
ICD10 31 C84.8
UMLS 71 C0079773

Summaries for Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

GARD: 19 Cutaneous T-cell lymphomas (CTCLs) are a group of disorders characterized by an abnormal accumulation of cancerous T-cells (a type of white blood cells) in the skin resulting in an itchy, red rash that can thicken or form a tumor. CTCLs belong to a larger group of disorders known asnon-Hodgkin's lymphomas. The most common types are mycosis fungoides and Sézary syndrome. In some cases, cancerous T-cells may spread to the lymph nodes and eventually to other body tissues and organs, potentially resulting in serious complications. The specific signs and symptoms vary from person to person. The exact cause of these conditions is unknown.

MalaCards based summary: Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, also known as cutaneous t-cell lymphoma, is related to primary cutaneous gamma-delta t-cell lymphoma and parapsoriasis. An important gene associated with Primary Cutaneous T-Cell Non-Hodgkin Lymphoma is TNFRSF8 (TNF Receptor Superfamily Member 8), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Denileukin diftitox and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and bone marrow, and related phenotypes are immune system and respiratory system

Disease Ontology: 11 A non-Hodgkin's lymphoma that has material basis in a mutation of T cells.

Wikipedia: 75 Cutaneous T-cell lymphoma (CTCL) is a class of non-Hodgkin lymphoma, which is a type of cancer of the... more...

Related Diseases for Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Diseases related to Primary Cutaneous T-Cell Non-Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 629)
# Related Disease Score Top Affiliating Genes
1 primary cutaneous gamma-delta t-cell lymphoma 32.9 TNFRSF8 TIA1 GZMB CD5
2 parapsoriasis 32.7 TNFRSF8 CD5
3 burkitt lymphoma 32.6 TNFRSF8 STAT3 IL7 IL4 IFNA1
4 lymphoma 32.6 TNFRSF8 TIA1 STAT3 IL2RA IL2 GZMB
5 fungal infectious disease 32.5 STAT3 IL4 IL2 IFNG H2AC18
6 sezary's disease 32.4 TNFRSF8 TIA1 STAT3 IL7 IL4 IL2RA
7 mycosis fungoides 32.2 TNFRSF8 TIA1 STAT3 ITGAE IL7 IL4
8 lymphoproliferative syndrome 31.8 TNFRSF8 TIA1 STAT3 IL2 CD5
9 lymphoproliferative syndrome, x-linked, 1 31.7 TNFRSF8 TIA1 GZMB CXCR3 CCR4
10 b-cell lymphoma 31.6 TNFRSF8 TIA1 STAT3 CXCR3 CD5
11 follicular mucinosis 31.5 TNFRSF8 TIA1 CD5
12 adult t-cell leukemia/lymphoma 31.5 TNFRSF8 IL2RA IL2 IL15 H2AC18 CD5
13 anaplastic large cell lymphoma 31.5 TNFRSF8 STAT3 IL2RA GZMB CXCR3 CCR4
14 t-cell acute lymphoblastic leukemia 31.4 TNFRSF8 STAT3 IL2RA IL2 HDAC9 H2AC18
15 lymphoma, hodgkin, classic 31.4 TNFRSF8 TIA1 STAT3 IL7 IL2RA IL2
16 panniculitis 31.4 TIA1 IL2RA IFNG GZMB
17 peripheral t-cell lymphoma 31.4 TNFRSF8 TIA1 STAT3 IL2RA H2AC18 GZMB
18 diphtheria 31.4 IL4 IL2RA IL2 IFNG IFNA1
19 exanthem 31.4 IL4 IL2 IFNG IFNA1 H2AC18
20 dermatitis 31.4 STAT3 IL4 IL2 IFNG GZMB CXCR3
21 dermatitis, atopic 31.3 TNFRSF8 STAT3 IL4 IL2RA IL2 IFNG
22 contact dermatitis 31.3 IL4 IL2 IFNG CXCR3 CCR4 CCL17
23 t-cell adult acute lymphocytic leukemia 31.3 TNFRSF8 TIA1 IL2 CD5 CCR4
24 hematologic cancer 31.2 TNFRSF8 IL7 IL2RA IL2 HDAC9 H2AC18
25 lymphoma, non-hodgkin, familial 31.2 TNFRSF8 STAT3 IL7 IL2RA IL2 IL15
26 neutropenia 31.2 IL4 IL2 IFNG IFNA2 IFNA1
27 acute graft versus host disease 31.2 IL2RA IL2 IFNG
28 lymphopenia 31.2 IL7 IL4 IL2RA IL2 IL15 IFNG
29 nasal type extranodal nk/t-cell lymphoma 31.2 TNFRSF8 TIA1 GZMB
30 histiocytosis 31.1 TNFRSF8 IL4 IFNG
31 thrombocytopenia 31.1 STAT3 IL7 IL4 IL2 IFNG IFNA2
32 reticulosarcoma 31.0 TNFRSF8 TIA1 GZMB
33 systemic scleroderma 31.0 IL4 IL2 IFNA1 H2AC18
34 skin disease 31.0 TNFRSF8 STAT3 ITGAE IL7 IL4 IL2
35 angioimmunoblastic t-cell lymphoma 31.0 TNFRSF8 TIA1 CD5
36 acquired immunodeficiency syndrome 31.0 IL2RA IL2 IL15 IFNG IFNA2 IFNA1
37 lichen planus 31.0 IL4 IL2 IFNG GZMB CXCR3
38 lymphadenitis 31.0 IL2RA IFNG CXCR3
39 hypereosinophilic syndrome 31.0 STAT3 IL4 IL2RA IL2 IFNG IFNA2
40 leukemia, acute lymphoblastic 31.0 IL7 IL2 HDAC9 H2AC18 CXCR3 CD5
41 psoriasis 30.9 STAT3 IL7 IL4 IL2RA IL2 IL15
42 allergic contact dermatitis 30.9 IL4 IL2 IFNG CXCR3 CCR4 CCL17
43 lymph node disease 30.9 IL2 IFNG H2AC18
44 pemphigoid 30.9 IL4 IL2 IFNG
45 peripheral nervous system disease 30.9 TNFRSF8 STAT3 IL4 IL2 IL15 IFNG
46 purpura 30.9 IL4 IL2 IFNG
47 severe combined immunodeficiency 30.9 TNFRSF8 STAT3 IL7 IL4 IL2RA IL2
48 hemophagocytic lymphohistiocytosis 30.8 IL7 IL2RA IL2 IFNG GZMB
49 t-cell prolymphocytic leukemia 30.8 TNFRSF8 H2AC18 CD5
50 mature t-cell and nk-cell lymphoma 30.8 TNFRSF8 TIA1 STAT3 IL2 HDAC9 H2AC18

Graphical network of the top 20 diseases related to Primary Cutaneous T-Cell Non-Hodgkin Lymphoma:



Diseases related to Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Symptoms & Phenotypes for Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

GenomeRNAi Phenotypes related to Primary Cutaneous T-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.17 CCL17 CCR10 CCR4 CD5 CXCR3 GZMB
2 no effect GR00402-S-2 10.17 CCR10 CCR4 CD5 GZMB H2AC18 HDAC9

MGI Mouse Phenotypes related to Primary Cutaneous T-Cell Non-Hodgkin Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.11 CCL17 CCR10 CCR4 CD5 CXCR3 GZMB
2 respiratory system MP:0005388 9.61 CCR4 CXCR3 IFNA1 IFNA2 IFNG IL2
3 hematopoietic system MP:0005397 9.58 CCL17 CCR10 CCR4 CD5 CXCR3 GZMB

Drugs & Therapeutics for Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Drugs for Primary Cutaneous T-Cell Non-Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 233)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Denileukin diftitox Approved, Investigational Phase 4 173146-27-5
2
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
3
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
4
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
5 Interferon alpha-2 Phase 4
6 Interferon-alpha Phase 4
7 Folic Acid Antagonists Phase 4
8 Folate Phase 4
9 Vitamin B9 Phase 4
10 Vitamin B Complex Phase 4
11 interferons Phase 4
12
Clorazepate Dipotassium Phase 4
13
Bexarotene Approved, Investigational Phase 3 153559-49-0 82146
14
Naloxone Approved, Vet_approved Phase 3 465-65-6 5284596
15
Hypericin Investigational Phase 3 548-04-9 5281051
16
Zanolimumab Investigational Phase 3 652153-01-0
17 Psychotropic Drugs Phase 3
18 Antidepressive Agents Phase 3
19 Immunoglobulins Phase 3
20 Antibodies, Monoclonal Phase 3
21 Antibodies Phase 3
22 Antineoplastic Agents, Immunological Phase 3
23 Opiate Alkaloids Phase 3
24 Narcotic Antagonists Phase 3
25 Narcotics Phase 3
26
Tazarotene Approved, Investigational Phase 1, Phase 2 118292-40-3 5381
27
Dimethyl fumarate Approved, Investigational Phase 2 624-49-7 637568
28
Triamcinolone Approved, Vet_approved Phase 2 124-94-7 31307
29
Mecobalamin Approved, Investigational Phase 2 13422-55-4
30
Hydroxocobalamin Approved Phase 2 13422-51-0 15589840 44475014
31
Tremelimumab Approved, Investigational Phase 1, Phase 2 745013-59-6
32
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
33
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
34
Rosiglitazone Approved, Investigational Phase 2 122320-73-4, 155141-29-0 77999
35
Adenosine Approved, Investigational Phase 2 58-61-7 60961
36
Pentostatin Approved, Investigational Phase 2 53910-25-1 439693
37
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
38
Prednisolone acetate Approved, Vet_approved Phase 1, Phase 2 52-21-1
39
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 4894 5755
40
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5 1875
41
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 4159 6741
42
Melphalan Approved Phase 2 148-82-3 4053 460612
43
Ondansetron Approved, Withdrawn Phase 2 99614-02-5 4595
44
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904
45
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
46
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
47
Mogamulizumab Approved, Investigational Phase 1, Phase 2 1159266-37-1
48
Alemtuzumab Approved, Investigational Phase 2 216503-57-0
49
Aminolevulinic acid Approved Phase 1, Phase 2 106-60-5 137
50
Letermovir Approved, Investigational Phase 2 917389-32-3 9916099 45138674

Interventional clinical trials:

(show top 50) (show all 304)
# Name Status NCT ID Phase Drugs
1 Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Subjects With Refractory Cutaneous T-Cell Lymphoma Completed NCT01007448 Phase 4 Bexarotene
2 UVADEX Sterile Solution in Conjunction With the UVAR XTS Photopheresis System as an Interventional Therapy for the Treatment Of CTCL (Mycosis Fungoides) in Patients With TMN Classification Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
3 Estimation of Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene Treatment of Cutaneous T Cell Lymphoma - Pilote Study Completed NCT01569724 Phase 4
4 A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25 Completed NCT00051012 Phase 4 ONTAK
5 A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25 Completed NCT00050999 Phase 4 ONTAK
6 Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
7 A Phase 4, Single Arm, Open Label, Multicenter Study of Brentuximab Vedotin Treatment of Chinese Patients With CD30-Positive Cutaneous T-Cell Lymphoma Recruiting NCT05442554 Phase 4 Brentuximab vedotin
8 Prospective, Randomized Multicentic to Compare PUVA+IFN Alpha 2a vs PUVA Alone in Mycosis Fungoides Stages Ia, Ib or IIa. Terminated NCT00630903 Phase 4 PUVA (8MOP + UVA) + IFN;PUVA (8-MOP + UVA)
9 Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas Terminated NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
10 Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions Unknown status NCT02867553 Phase 3 rituximab
11 A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma Completed NCT01871727 Phase 3 E7777 9 mcg/kg
12 A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma Completed NCT02448381 Phase 3 SGX301 (synthetic hypericin);Placebo
13 Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma Completed NCT01728805 Phase 3 Vorinostat
14 A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Completed NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate;Bexarotene
15 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
16 TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides: a Prospective Randomized Controlled Study Not yet recruiting NCT05205902 Phase 3
17 A Phase III Study of Lenalidomide Maintenance After Debulking Therapy in Patients With Advanced Cutaneous T-Cell Lymphoma Terminated NCT01098656 Phase 3 lenalidomide
18 A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma Terminated NCT02811783 Phase 3 Naloxone Hydrochloride Lotion, 0.5%;Placebo Lotion
19 Open Label, Dose Escalation, Followed by Open Label,Single Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin® (Bexarotene) and One Other Standard Therapy Terminated NCT00127881 Phase 3 HuMax-CD4 (zanolimumab)
20 Progression Free Survival (PFS) Comparison Between Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat TM) in Combination With Bortezomib (Velcade TM) and SAHA Alone in Refractory or Recurrent Advanced CTCL. A Randomized Study. Withdrawn NCT01386398 Phase 3 bortezomib;vorinostat
21 Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study Unknown status NCT00779896 Phase 1, Phase 2 Tazarotene
22 A Single Arm, Open-Label Study To Evaluate The Safety, Tolerability And Preliminary Efficacy Of NM-IL-12 (rHuIL-12) In Patients With Cutaneous T Cell Lymphoma (CTCL) Undergoing Low Dose Total Skin Electron Beam Therapy (TSEBT) Unknown status NCT02542124 Phase 2
23 Phase IIA Study on Therapy With the NF-κB Inhibiting and Apoptosis Inducing Drug Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) Unknown status NCT02546440 Phase 2 dimethylfumarate
24 Open-label Phase 2 Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma Unknown status NCT01132989 Phase 2 Lenalidomide
25 A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma Unknown status NCT02213861 Phase 2 SHAPE
26 Phase II Study of Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides Unknown status NCT02881749 Phase 2 mechlorethamine gel 0.016%
27 A Muliticenter, Dose-Reandomized Evaluation Of Targretin Capsules Plus PUVA In Patients With Stage IB - IIA Cutaneous T-Cell Lymphoma Unknown status NCT00030589 Phase 2 bexarotene;methoxsalen
28 A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Unknown status NCT03278782 Phase 1, Phase 2 Romidepsin
29 Valchlor Therapy in Conjunction With Triamcinolone 0.1% Ointment for the Treatment of Contact Dermatitis in Patients With Early Stage Cutaneous T-cell Lymphoma (Mechlorethamine Induced Dermatitis Avoidance Study) Completed NCT03380026 Phase 2 Triamcinolone;Valchlor 0.016 % Topical Gel
30 A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma Completed NCT00425555 Phase 2 Panobinostat
31 A Phase 2 Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma Completed NCT02676778 Phase 2 E7777
32 A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients With Aggressive Non-Hodgkin's Lymphoma Completed NCT00807495 Phase 2 Alisertib
33 A Phase 2, Open-Label, Multicenter Study of Single-Agent Enzastaurin in Patients With Relapsed Cutaneous T-Cell Lymphoma Completed NCT00744991 Phase 2 Enzastaurin
34 A Multicenter Open Label Phase II Study of to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Refractory or Relapsed Cutaneous T-cell Lymphoma Completed NCT00431912 Phase 2 APO866
35 A Randomized, Double-blind, Multi-centre, Placebo-controlled, Parallel-arm Phase 2 Trial to Assess Safety, Efficacy and Pharmacokinetics of CD11301 0.03% and 0.06% Gel in the Treatment of Cutaneous T-Cell Lymphoma (CTCL), Stages IA, IB and IIA Completed NCT03292406 Phase 2 Placebo;CD11301 0.03%;CD11301 0.06%
36 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist Poly-ICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Completed NCT02643303 Phase 1, Phase 2 Durvalumab;Tremelimumab;Poly-ICLC
37 Single Agent Phase II Study of Forodesine (BCX1777) in the Treatment of Cutaneous T-Cell Lymphoma Completed NCT00501735 Phase 2 Forodesine 200 mg
38 Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. Completed NCT00071084 Phase 2 HuMax-CD4
39 Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. Completed NCT00071071 Phase 2 HuMax-CD4
40 Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma Completed NCT00007345 Phase 2 Romidepsin
41 Open Label Pilot Study of Combination Therapy With Rosiglitazone and Bexarotene to Investigate a Possible Synergism in the Treatment of Cutaneous T-Cell Lymphoma Completed NCT00178841 Phase 2 Rosiglitazone and Bexarotene
42 Phase IIb Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-cell Lymphoma Completed NCT00091559 Phase 2 MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months
43 A Phase II Study of Deoxycoformycin (DCF) in Lymphoid Malignancies Completed NCT00038025 Phase 2 Deoxycoformycin (DCF)
44 A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma Completed NCT00611208 Phase 2
45 Phase I/II Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma Completed NCT00306969 Phase 1, Phase 2 bexarotene
46 A Phase I/IIa, Dose-Ranging Safety and Efficacy Study of Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma Completed NCT01676831 Phase 1, Phase 2 Topical resiquimod 0.06%;topical resiquimod 0.03%
47 A Single Agent Phase II Study of Depsipeptide (FK228) in the Treatment of Cutaneous T-cell Lymphoma Completed NCT00106431 Phase 2 romidepsin (depsipeptide, FK228)
48 Phase II Evaluation of Immunization Against Tumor Cells in Subjects With Sezary Syndrome Using Autologous Mature Dendritic Cells Completed NCT00099593 Phase 2
49 A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms Completed NCT03493451 Phase 2 Tislelizumab
50 A Phase I/II Study of RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Completed NCT01198665 Phase 1, Phase 2 RAD001 (Everolimus)

Search NIH Clinical Center for Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


bexarotene
DENILEUKIN

Cochrane evidence based reviews: lymphoma, t-cell, cutaneous

Genetic Tests for Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Anatomical Context for Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Organs/tissues related to Primary Cutaneous T-Cell Non-Hodgkin Lymphoma:

MalaCards : T Cells, Skin, Bone Marrow, Liver, Nk Cells, Myeloid, Bone

Publications for Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Articles related to Primary Cutaneous T-Cell Non-Hodgkin Lymphoma:

(show top 50) (show all 4898)
# Title Authors PMID Year
1
STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL. 53 62
20213502 2010
2
Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. 53 62
20212249 2010
3
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. 53 62
20308564 2010
4
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. 53 62
20132536 2010
5
HDAC inhibitors in cancer care. 53 62
20361469 2010
6
Response to hydralazine-valproate in a patient with mycosis fungoides. 53 62
20339522 2010
7
Histone deacetylase inhibitors in cancer therapy. 53 62
19826124 2009
8
Histone deacetylase inhibitors: current status and overview of recent clinical trials. 53 62
19747008 2009
9
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. 53 62
19220424 2009
10
Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors. 53 62
19242508 2009
11
Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. 53 62
18923451 2009
12
Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. 53 62
19689336 2009
13
Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. 53 62
19344187 2009
14
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. 53 62
18839006 2008
15
Differential CCR4 expression and function in cutaneous T-cell lymphoma cell lines. 53 62
19239991 2008
16
Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells. 53 62
18496567 2008
17
Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level. 53 62
18838793 2008
18
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. 53 62
18671804 2008
19
Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. 53 62
18569641 2008
20
Novel purine nucleoside analogues for hematological malignancies. 53 62
18537755 2008
21
Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. 53 62
18281483 2008
22
Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies. 53 62
18086344 2007
23
Chemokine receptor expression by leukemic T cells of cutaneous T-cell lymphoma: clinical and histopathological correlations. 53 62
17597825 2007
24
Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12. 53 62
18021470 2007
25
Trithiocarbonates: exploration of a new head group for HDAC inhibitors. 53 62
17606370 2007
26
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. 53 62
17594194 2007
27
Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sézary syndrome. 53 62
17367611 2007
28
Skin-homing CD8+ T lymphocytes show preferential growth in vitro and suppress CD4+ T-cell proliferation in patients with early stages of cutaneous T-cell lymphoma. 53 62
17340017 2007
29
Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? 53 62
17109024 2007
30
Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas. 53 62
16673127 2006
31
Molecular analysis of T-cell receptor beta genes in cutaneous T-cell lymphoma reveals Jbeta1 bias. 53 62
16741518 2006
32
Immunotoxins for targeted cancer therapy. 53 62
17025272 2006
33
Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. 53 62
16859899 2006
34
The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. 53 62
16645590 2006
35
Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties. 53 62
16830050 2006
36
[Extensive cutaneous candidiasis revealing cutaneous T-cell lymphoma: 2 cases]. 53 62
16885846 2006
37
The influence of STAT5 antisense oligodeoxynucleotides on the proliferation and apoptosis of selected human cutaneous T-cell lymphoma cell lines. 53 62
16502315 2006
38
Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. 53 62
16322477 2006
39
CCR10 is expressed in cutaneous T-cell lymphoma. 53 62
15700309 2005
40
Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. 53 62
15727636 2005
41
Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma. 53 62
16088151 2005
42
Efficacy of different targeting agents in the photolysis of interleukin-2 receptor bearing cells. 53 62
15542358 2004
43
Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. 53 62
15328153 2004
44
Methylation status of the p15, p16 and MGMT promoter genes in primary cutaneous T-cell lymphomas. 53 62
15531468 2004
45
In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. 53 62
15141228 2004
46
Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. 53 62
15243520 2004
47
Recombinant immunotoxins for the treatment of haematological malignancies. 53 62
15268678 2004
48
Extracorporeal photopheresis differentially regulates the expression of phosphorylated STAT-1 and STAT-5 in treated monocytes and T cells, respectively. 53 62
15578129 2004
49
Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. 53 62
14710894 2003
50
Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. 53 62
12841391 2003

Variations for Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Copy number variations for Primary Cutaneous T-Cell Non-Hodgkin Lymphoma from CNVD:

6 (show all 49)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 21732 1 16100000 20300000 Amplification Cutaneous T-cell lymphoma
2 25426 1 189000000 192100000 Deletion Cutaneous T-cell lymphoma
3 38869 10 105700000 111800000 Deletion Cutaneous T-cell lymphoma
4 39996 10 12300000 17300000 Deletion Cutaneous T-cell lymphoma
5 41377 10 17300000 19900000 Amplification Cutaneous T-cell lymphoma
6 42285 10 31400000 34500000 Deletion Cutaneous T-cell lymphoma
7 47113 10 89600000 92900000 Deletion PTEN Cutaneous T-cell lymphoma
8 61605 12 10000000 12600000 Deletion ETV6 Cutaneous T-cell lymphoma
9 71417 12 69800000 74100000 Deletion Cutaneous T-cell lymphoma
10 77639 13 46200000 48900000 Deletion RB1 Cutaneous T-cell lymphoma
11 83022 14 19100000 23600000 Deletion NDRG2 Cutaneous T-cell lymphoma
12 83023 14 19100000 23600000 Deletion ZNF219 Cutaneous T-cell lymphoma
13 97437 16 10300000 12500000 Deletion Cutaneous T-cell lymphoma
14 98274 16 16700000 20500000 Deletion Cutaneous T-cell lymphoma
15 107006 17 11200000 15900000 Deletion MAP2K4 Cutaneous T-cell lymphoma
16 108845 17 23200000 28800000 Amplification DHRS13 Cutaneous T-cell lymphoma
17 108846 17 23200000 28800000 Amplification ERAL1 Cutaneous T-cell lymphoma
18 108847 17 23200000 28800000 Amplification FLOT2 Cutaneous T-cell lymphoma
19 108848 17 23200000 28800000 Amplification PHF12 Cutaneous T-cell lymphoma
20 112029 17 37800000 41900000 Amplification Cutaneous T-cell lymphoma
21 116538 17 6800000 11200000 Deletion TP53 Cutaneous T-cell lymphoma
22 120627 18 2900000 7200000 Amplification Cutaneous T-cell lymphoma
23 123359 18 71300000 76117153 Deletion PARD6G Cutaneous T-cell lymphoma
24 133686 19 6900000 12600000 Deletion Cutaneous T-cell lymphoma
25 142291 2 221300000 224900000 Deletion Cutaneous T-cell lymphoma
26 152036 20 28400000 31500000 Amplification BCL2L1 Cutaneous T-cell lymphoma
27 162458 22 21800000 24300000 Amplification Cutaneous T-cell lymphoma
28 162461 22 21800000 24300000 Deletion Cutaneous T-cell lymphoma
29 171538 3 169200000 172500000 Amplification PRKCI Cutaneous T-cell lymphoma
30 180261 4 102500000 107900000 Amplification Cutaneous T-cell lymphoma
31 180582 4 107900000 114100000 Amplification Cutaneous T-cell lymphoma
32 181002 4 114100000 120600000 Amplification Cutaneous T-cell lymphoma
33 184833 4 182600000 187300000 Deletion Cutaneous T-cell lymphoma
34 186902 4 40900000 45600000 Deletion Cutaneous T-cell lymphoma
35 190065 4 82600000 84300000 Deletion Cutaneous T-cell lymphoma
36 203973 6 104800000 113900000 Deletion Cutaneous T-cell lymphoma
37 206027 6 135200000 139100000 Deletion Cutaneous T-cell lymphoma
38 211016 6 31900000 33600000 Deletion Cutaneous T-cell lymphoma
39 212690 6 40600000 45200000 Deletion VEGFA Cutaneous T-cell lymphoma
40 222425 7 15200000 19500000 Deletion Cutaneous T-cell lymphoma
41 225996 7 53900000 57400000 Amplification EGFR Cutaneous T-cell lymphoma
42 233736 8 127300000 131500000 Amplification MYC Cutaneous T-cell lymphoma
43 237881 8 27400000 29700000 Deletion Cutaneous T-cell lymphoma
44 238080 8 29700000 38500000 Deletion Cutaneous T-cell lymphoma
45 239603 8 39900000 43200000 Deletion Cutaneous T-cell lymphoma
46 243701 8 87200000 93500000 Amplification Cutaneous T-cell lymphoma
47 244139 8 93500000 99100000 Deletion Cutaneous T-cell lymphoma
48 249980 9 19900000 25500000 Deletion CDKN2A Cutaneous T-cell lymphoma
49 255727 9 83400000 86100000 Deletion Cutaneous T-cell lymphoma

Expression for Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Search GEO for disease gene expression data for Primary Cutaneous T-Cell Non-Hodgkin Lymphoma.

Pathways for Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Pathways related to Primary Cutaneous T-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 TNFRSF8 STAT3 IL7 IL4 IL2RA IL2
2
Show member pathways
13.82 TNFRSF8 STAT3 ITGAE IL7 IL4 IL2RA
3 13.79 TIA1 STAT3 IL2RA IL2 HDAC9 H2AC18
4
Show member pathways
13.53 STAT3 ITGAE IL7 IL4 IL2RA IL2
5
Show member pathways
13.34 TNFRSF8 STAT3 IL7 IL4 IL2RA IL2
6
Show member pathways
13.29 TNFRSF8 STAT3 IL7 IL4 IL2RA IL2
7
Show member pathways
13.26 TNFRSF8 IL7 IL4 IL2RA IL2 IL15
8
Show member pathways
13.18 CCL17 CCR10 CCR4 CXCR3 IL15 IL2
9
Show member pathways
12.97 ITGAE IL7 IL4 IL2RA IL2 IFNA2
10
Show member pathways
12.87 IL15 IL2 IL2RA IL4 IL7 STAT3
11
Show member pathways
12.83 STAT3 CXCR3 CCR4 CCR10 CCL17
12
Show member pathways
12.82 STAT3 IL2RA IL2 IFNA2 IFNA1
13
Show member pathways
12.63 IFNA1 IFNA2 IFNG IL15 IL2 IL2RA
14 12.48 TNFRSF8 STAT3 IL4 IL2RA IL2 IFNG
15
Show member pathways
12.27 STAT3 IL2RA IL2 IL15
16
Show member pathways
12.07 CXCR3 CCR4 CCR10 CCL17
17
Show member pathways
12.07 STAT3 IL4 IL2RA IL2 IFNG
18
Show member pathways
11.96 STAT3 IL4 IL2RA IL2 IFNG GZMB
19 11.92 IL4 IL2RA IL2 IFNG GZMB
20
Show member pathways
11.9 STAT3 IL4 IFNG GZMB
21
Show member pathways
11.88 STAT3 IL2 IFNG
22 11.86 STAT3 IL15 CCR4
23 11.83 IFNG IFNA2 IFNA1
24 11.8 ITGAE IL2 IFNG IFNA2
25 11.75 IL4 IL2 IFNG
26 11.74 IFNG IL2 STAT3
27
Show member pathways
11.74 IL4 IL2RA IL2 IFNG
28 11.71 IL4 IL2 IFNG
29 11.71 STAT3 IL4 IL2RA IL2 IFNG
30 11.69 IL4 IL2 IFNG
31
Show member pathways
11.68 STAT3 IL4 IL2 IFNG
32 11.62 IL7 IL4 IL2RA IL2 IL15 IFNG
33 11.58 IL2RA IL2 IFNG
34 11.57 IL4 IL2RA IL2 IFNG
35 11.53 STAT3 IL4 IL2RA
36 11.52 CCL17 IFNG IL2 IL2RA IL4
37 11.4 IL4 IL2RA IL2 IFNG
38 11.38 IFNG IL15 IL4 IL7
39
Show member pathways
11.36 IL2RA IL2 IL15 IFNG GZMB
40 11.27 STAT3 IL2RA IL2 IFNG
41 11.26 IL4 IL2 IFNG
42 11.24 IL4 IL2 IFNG
43 11.22 STAT3 IL2RA IFNG
44 11.18 IL7 IL4 IL2 IL15 IFNG
45 11.18 ITGAE IL7 IL4 IL2RA IL2 IL15
46 11.04 ITGAE IL7 IL4 IL2 IL15 CCL17
47 10.97 IFNG IL2 IL4
48 10.77 IL2RA IL2 IFNG
49 10.69 IL2RA IL2

GO Terms for Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Cellular components related to Primary Cutaneous T-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.4 ITGAE IL2RA CXCR3 CD5 CCR4 CCR10

Biological processes related to Primary Cutaneous T-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 10.21 IL7 IL2 IL15 IFNA2 CCL17
2 positive regulation of cytosolic calcium ion concentration GO:0007204 10.19 IL2 CXCR3 CCR4 CCR10
3 cytokine-mediated signaling pathway GO:0019221 10.19 STAT3 IL7 IFNA2 IFNA1
4 chemotaxis GO:0006935 10.1 CXCR3 CCR4 CCR10 CCL17
5 B cell differentiation GO:0030183 10.08 IL4 IFNA2 IFNA1 HDAC9
6 inflammatory response GO:0006954 10.06 CCL17 CCR4 CXCR3 HDAC9 IFNA2 IL15
7 B cell proliferation GO:0042100 10.04 IL7 IFNA2 IFNA1
8 positive regulation of B cell proliferation GO:0030890 10.02 IL2 IL4 IL7
9 chemokine-mediated signaling pathway GO:0070098 10.01 CXCR3 CCR4 CCR10 CCL17
10 humoral immune response GO:0006959 9.92 IL7 IFNG IFNA2 IFNA1
11 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.91 IFNA1 IFNA2 IFNG
12 neuroinflammatory response GO:0150076 9.88 IL4 IFNG
13 positive regulation of T cell proliferation GO:0042102 9.85 IL4 IL2RA IL2 IL15
14 positive regulation of tissue remodeling GO:0034105 9.83 IL2 IL15
15 regulation of T cell homeostatic proliferation GO:0046013 9.8 IL2RA IL2
16 positive regulation of T cell differentiation GO:0045582 9.8 IL7 IL4 IL2RA IL2
17 regulation of CD4-positive, alpha-beta T cell proliferation GO:2000561 9.76 IL2RA IL2
18 negative regulation of lymphocyte proliferation GO:0050672 9.71 IL2RA IL2
19 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 IL4 IL2 IL15 IFNG IFNA2
20 lymphocyte proliferation GO:0046651 9.6 IL2RA IL2
21 immune response GO:0006955 9.55 IL7 IL4 IL2RA IL2 IL15 IFNG

Molecular functions related to Primary Cutaneous T-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.83 IL7 IL4 IL2 IL15 IFNG IFNA2
2 C-C chemokine binding GO:0019957 9.8 CXCR3 CCR4 CCR10
3 C-C chemokine receptor activity GO:0016493 9.73 CXCR3 CCR4 CCR10
4 chemokine receptor activity GO:0004950 9.55 CXCR3 CCR4 CCR10
5 cytokine receptor binding GO:0005126 9.1 IL7 IL4 IL15 IFNA2 IFNA1

Sources for Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....